Perhaps I should explain a little bit about how that part of the act becomes operational within the new substances program. It happens whenever a risk assessor believes there is a reason for concern that isn't addressed adequately by the test information that has been received or the adequacy of our predictive models. We would then go back to a company and require different types of testing and more information to be able to make a determination.
We've always viewed that piece of the legislation not so much as an invitation to conduct ongoing research as much as to address a particular concern that we are becoming aware of, usually because of emerging science such as areas like perfluorinated compounds, which only became of concern recently because of information coming to us. We've gone out and asked for more information in that context.
So that's how we tend to apply it. And if we were to apply that in a broader context, I'm not sure we would know exactly what to ask for that would help us make a determination.